anaemia Archives -

Bristol-Myers Squibb/ Cancer/ News/ News/ News/ Oncology/ R&D/ Top pharmaceutical companies

BMS announces positive Reblozyl phase 3 results for MDS

Nicole Raleigh anaemia, blood cancer, blood transfusions, Bristol-Myers Squibb, clinical trial, myelodyplastic syndromes, Reblozyl, red blood cells 0 Comment

Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first

BMS announces positive Reblozyl phase 3 results for MDS

https://pharmaphorum.com/news/bms-announces-positive-reblozyl-phase-3-results-for-mds/

Market Access/ News/ News/ News/ R&D

GSK shelves arthritis blockbuster hope otilimab after lacklustre data

Phil Taylor anaemia, chronic kidney disease, daprodustat, GlaxoSmithKline, MorphoSys, otilimab, Rheumatoid arthritis 0 Comment

GSK has said it will not be able to move ahead with regulatory filings for otilimab as a

GSK shelves arthritis blockbuster hope otilimab after lacklustre data

https://pharmaphorum.com/news/gsks-shelves-arthritis-blockbuster-hope-otilimab-after-lacklustre-data/

Market Access/ News/ News

GSK’s daprodustat will have to face FDA advisory committee

Phil Taylor anaemia, chronic kidney disease, daprodustat, fda, GlaxoSmithKline, nephrology, regulatory 0 Comment

GSK has said that its daprodustat for anaemia associated with chronic kidney disease (CKD) will have to face

GSK’s daprodustat will have to face FDA advisory committee

https://pharmaphorum.com/news/gsks-daprodustat-will-face-fda-advisory-committee/

Market Access/ News/ News/ News/ Oncology

GSK gets June 2023 FDA decision date for momelotinib

Phil Taylor anaemia, GlaxoSmithKline, momelotinib, myelofibrosis, regulatory, Sierra Oncology 0 Comment

The clock is now ticking on the FDA’s review of GSK’s momelotinib for myelofibrosis patients with anaemia –

GSK gets June 2023 FDA decision date for momelotinib

https://pharmaphorum.com/news/gsk-gets-june-2023-fda-decision-date-for-momelotinib/

Market Access/ News/ News

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

Phil Taylor anaemia, Astellas, chronic kidney disease, Evrenzo, HEOR, NHS, NICE 0 Comment

Astellas’ oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

https://pharmaphorum.com/news/nice-backs-astellas-oral-therapy-evrenzo-for-anaemia-in-kidney-disease/

Market Access/ News/ News

GSK goes for gold as FDA starts review of daprodustat

Phil Taylor Akebia Therapeutics, anaemia, AstraZeneca, chronic kidney disease, daprodustat, FibroGen, GlaxoSmithKline, roxadustat, vadadustat 0 Comment

GlaxoSmithKline says the FDA has started its review of daprodustat for anaemia associated with chronic kidney disease (CKD),

GSK goes for gold as FDA starts review of daprodustat

https://pharmaphorum.com/news/fda-starts-review-of-gsks-kidney-drug-daprodustat/

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

Market Access/ News/ News

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

Phil Taylor Akebia Therapeutics, anaemia, Astellas, chronic kidney disease, daprodustat, EU, FibroGen, GlaxoSmithKline, Haematology, regulatory approval, roxadustat, vadadustat 0 Comment

The EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

https://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/

News

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

Richard Staines anaemia, Astellas, AstraZeneca, chronic kidney disease, Duvroq, FibroGen, GlaxoSmithKline, Kyowa Kirin 0 Comment

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

https://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/

Market Access/ News/ News

Celgene scores FDA okay for thalassaemia drug Reblozyl

Phil Taylor Acceleron, anaemia, beta thalassaemia, Celgene, FDA approval 0 Comment

The FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the

Celgene scores FDA okay for thalassaemia drug Reblozyl

https://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/

Trending

anaemia

Login